Letrozole

ONCOLOGY
more

Letrozole is a aromatase Inhibitor. It is used in the treatment of breast cancer. inhibits the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization

Imatinib mesylate

ONCOLOGY
more

Imatinib is a tyrosine kinase inhibitor. It inhibits the activity of the  Bcr-Abl tyrosine kinase (TK)

Sorafenib tosylate

ONCOLOGY
more

Sorafenib is a tyrosine kinase inhibitor, Angiogenesis Inhibitor and VEGF inhibitor. It inhibits multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases 

Nilotinib.HCl.H2O

ONCOLOGY
more

Nilotinib is a tyrosine kinase inhibitor. It inhibits the ABL tyrosine kinase activity of the BCR-ABL oncoprotein both in cell lines and in primary Philadelphia-chromosome positive leukaemia cells

Erlotinib.HCl

ONCOLOGY
more

Erlotinib is a tyrosine kinase inhibitor, epidermal growth factor receptor inhibitor, EGFR inhibitor and EGF receptor inhibitor. It inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal

Sunitinib malate

ONCOLOGY
more

Sunitinib is a multi-receptor tyrosine kinase (RTK) inhibitor. It inhibits CD117 (c-KIT) , the receptor tyrosine kinase and all receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors

Gefitinib

ONCOLOGY
Gefitinib
more

Gefitinib is a tyrosine kinase inhibitor. It inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme

Palbociclib

ONCOLOGY
Palbociclib
more

Palbociclib is a cyclin-dependent kinase 4/6 inhibitor or CDK4/6 inhibitor.it is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, that acts by binding to the ATP pocket with an IC50

Ibrutinib

ONCOLOGY
Ibrutinib
more

Ibrutinib is a burton’s tyrosine kinase inhibitor. it forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity

Lenalidomide

ONCOLOGY
more

Lenalidomide inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma

Pazopanib.HCl

ONCOLOGY
more

Pazopanib is a multi-receptor tyrosine kinase inhibitor. It inhibits multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor

Regorafenib

ONCOLOGY
more

Regorafenib is a multiple receptor tyrosine kinase inhibitor. It inhibits the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAF 

Dasatinib.H2O

ONCOLOGY
more

Dasatinib is a tyrosine kinase inhibitor. It inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ.

Dasatinib anhydrous

ONCOLOGY
more

Dasatinib is a tyrosine kinase inhibitor. It inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ

VANDETANIB

ONCOLOGY
more

Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2, and EGFR; TKI inhibition blocks angiogenesis and cellular proliferation

OSIMERTINIB

ONCOLOGY
more

Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of 

 

CRIZOTINIB

ONCOLOGY
crizotinib
more

Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor.

 

Empagliflozin

Anti-diabetic
Empagliflozin
more

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose

Dapagliflozin

Anti-diabetic
Dapagliflozin
more

Dapagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor. It reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion

Linagliptin

Anti-diabetic
more

Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependent insulinotropic polypeptide

Teriflunomide

Multiple Sclerosis
Teriflunomide
more

Teriflunomide is a pyrimidine synthesis inhibitor. It is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase 

Dimethyl fumarate

Multiple Sclerosis
Dimethyl fumarate
more

Dimethyl fumarate is an anti-inflammatory. It can activate the transcription factor (Nuclear factor erythroid-derived 2)-related factor 2 (Nrf2) pathway

Fingolimod.HCl

Multiple Sclerosis
Fingolimod.HCl
more

Fingolimod is a sphingosine l-phosphate receptor modulator. It is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. 

Rivaroxaban

Cardiovascular
more

Rivaroxaban is a direct Factor Xa Inhibitor. It inhibits free FXa and prothrombinase activity

APIXABAN

Cardiovascular
APIXABAN
more

Apixaban is a selective inhibitor of factor Xa. It does not require anti thrombin III for antithrombotic activity. Apixaban inhibits free

Favipiravir

Covid 19
Favipiravir
more

Favipiravir is an antiviral agent. the active favipiravir-RTP selectively inhibits RNA polymerase and prevents replication of the viral genome

Molnupiravir 

Covid 19
molnupiravir
more

Molnupiravir inhibits the replication of the SARS-CoV-2 virus, the causative agent of COVID-19

Riluzole

Central nervous
more

Riluzole is an antiglutamate. motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate so riluzole inhibits  glutamate release

Tofacitinib citrate

Anti-rheumatic
Tofacitinib citrate
more

Tofacitinib is a janus kinase inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions. 

Roxadustat

Anti-Anemic
more

Roxadustat is the first in a new class of treatments, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased